NCT02915744
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Phase: Phase 3
Role: Lead Sponsor
Start: Nov 30, 2016
Completion: Jul 31, 2020